Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

News in Brief

This article was originally published in The Gold Sheet

Executive Summary

FDA hits heparin supply chain; Ranbaxy consents to data integrity oversight; multinationals find solutions to China’s vaccine compendial crisis; EU seeks comment on safety measures, API imports.

You may also be interested in...



API Firms Advised to Gear Up for Inspections Under GDUFA and FMD

The Anti-Falsification Directive: Europe’s Answer to Global Supply Chain Threats

The European Union July 1 published its directive on falsified medicines, setting into motion a tightening of Europe’s pharmaceutical supply chain that will for the most part take place over the next 18 months – and that could cost pharmaceutical companies billions of Euros.

Data Integrity Problems Continued to Surface in Recent Warning Letters

Recent GMP warning letters featured data integrity issues.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS000665

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel